Cocrystal Pharma Stock In The News

COCP Stock  USD 2.07  0.03  1.43%   
Our overall analysis of Cocrystal Pharma's news coverage and content from conventional and social sources shows investors' bearish mood towards Cocrystal Pharma. The specific impact of Cocrystal Pharma news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Cocrystal Pharma's overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Cocrystal Pharma headlines in addition to utilizing other, more conventional financial analysis modules. Check out Cocrystal Pharma Backtesting and Cocrystal Pharma Hype Analysis.
To learn how to invest in Cocrystal Stock, please use our How to Invest in Cocrystal Pharma guide.

Cocrystal Pharma Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast
https://www.globenewswire.com/news-release/2023/11/29/2787694/0/en/Cocrystal-Pharma-Highlights-its-Novel-Inhaled-and-Oral-Influenza-A-Antiviral-CC-42344-at-the-World-Vaccine-Congress-West-Coast.html
 Neutral
Macroaxis News: globenewswire.com
Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023
https://www.globenewswire.com/news-release/2023/11/27/2786112/0/en/Cocrystal-Pharma-to-Present-at-the-NobleCon-19-Conference-on-December-4-2023.html
 Neutral
Macroaxis News: globenewswire.com
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
https://www.globenewswire.com/news-release/2023/11/13/2779026/0/en/Cocrystal-Pharma-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Updates-on-its-Antiviral-Drug-Development-Programs.html
 Neutral
Macroaxis News: globenewswire.com
Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast
https://www.globenewswire.com/news-release/2023/11/09/2777282/0/en/Cocrystal-Pharma-to-Discuss-Progress-with-Novel-Inhaled-and-Oral-Influenza-A-Antiviral-CC-42344-at-the-World-Vaccine-Congress-West-Coast.html
 Neutral
Macroaxis News: globenewswire.com
Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344
https://www.globenewswire.com/news-release/2023/10/31/2770088/0/en/Cocrystal-Pharma-Receives-UK-MHRA-Authorization-to-Initiate-Its-Phase-2a-Influenza-Human-Challenge-Trial-with-Oral-PB2-Inhibitor-CC-42344.html
 Neutral
Macroaxis News: globenewswire.com
Cocrystal Pharma Doses First Subjects in Clinical Study of CDI-988 For Pandemic Norovirus and Coronavirus
https://www.globenewswire.com/news-release/2023/09/28/2751169/0/en/Cocrystal-Pharma-Doses-First-Subjects-in-Clinical-Study-of-CDI-988-For-Pandemic-Norovirus-and-Coronavirus.html
 Neutral
Macroaxis News: globenewswire.com
Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference
https://www.globenewswire.com/news-release/2023/09/05/2737249/0/en/Cocrystal-Pharma-to-Participate-in-the-H-C-Wainwright-Global-Investment-Conference.html
 Bullish
Macroaxis News: globenewswire.com
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
https://www.globenewswire.com/news-release/2023/08/14/2724340/0/en/Cocrystal-Pharma-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Updates-on-its-Antiviral-Drug-Development-Programs.html
 Neutral
Macroaxis News: globenewswire.com
Cocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 as Norovirus Lead
https://www.globenewswire.com/news-release/2023/08/08/2720588/0/en/Cocrystal-Pharma-Selects-Novel-Oral-Protease-Inhibitor-CDI-988-as-Norovirus-Lead.html
 Neutral
Macroaxis News: globenewswire.com
Cocrystal Pharma Receives HREC Approval to Initiate Phase 1 Study to Evaluate Oral Broad-Spectrum Coronavirus 3CL Protease Inhibitor CDI-988
https://www.globenewswire.com/news-release/2023/05/31/2679355/0/en/Cocrystal-Pharma-Receives-HREC-Approval-to-Initiate-Phase-1-Study-to-Evaluate-Oral-Broad-Spectrum-Coronavirus-3CL-Protease-Inhibitor-CDI-988.html
 Neutral

Cocrystal Pharma Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Cocrystal and other traded companies coverage with news coverage. We help investors stay connected with Cocrystal headlines for the 2nd of December to make an informed investment decision based on correlating the impacts of news items on Cocrystal Stock performance. Please note that trading solely based on the Cocrystal Pharma hype is not for everyone as timely availability and quick action are needed to avoid losses.
Cocrystal Pharma's linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Cocrystal Pharma investors visualize upcoming and past events in order to time the market based on Cocrystal Pharma noise-free hype analysis.
Cocrystal Pharma stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Cocrystal earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Cocrystal Pharma that are available to investors today. That information is available publicly through Cocrystal media outlets and privately through word of mouth or via Cocrystal internal channels. However, regardless of the origin, that massive amount of Cocrystal data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Cocrystal Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Cocrystal Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Cocrystal Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Cocrystal Pharma alpha.

Cocrystal Largest EPS Surprises

Earnings surprises can significantly impact Cocrystal Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-08-14
2024-06-30-0.48-0.53-0.0510 
2022-05-11
2022-03-31-0.42-0.48-0.0614 
2021-08-16
2021-06-30-0.42-0.48-0.0614 
2021-05-17
2021-03-31-0.54-0.480.0611 
2024-11-11
2024-09-30-0.57-0.490.0814 
2023-11-13
2023-09-30-0.53-0.410.1222 
View All Earnings Estimates

Cocrystal Pharma Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Cocrystal Pharma Stock. Current markets are slightly bearish. About 51% of major world exchanges and indexes are down. See today's market update for more information.
Macroaxis News
29th of November 2024
Acquisition by Linscott Walt Addison of 1200000 shares of Cocrystal Pharma at 0.98 subject...
at MacroaxisInsider 
seekingalpha News
13th of November 2024
Cocrystal Pharma GAAP EPS of -0.49 beats by 0.08
at seekingalpha.com 
Macroaxis News: globenewswire.com
31st of October 2024
Cocrystal Pharmas Co-CEOs Highlight Pioneering Approach to Antiviral Drug Candidates Targe...
at globenewswire.com 
Macroaxis News
10th of October 2024
Acquisition by Block David S of 108696 shares of Cocrystal Pharma at 0.92 subject to Rule ...
at MacroaxisInsider 
Yahoo News
26th of September 2024
Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-...
at finance.yahoo.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Cocrystal Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Cocrystal Pharma's short interest history, or implied volatility extrapolated from Cocrystal Pharma options trading.

Additional Tools for Cocrystal Stock Analysis

When running Cocrystal Pharma's price analysis, check to measure Cocrystal Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cocrystal Pharma is operating at the current time. Most of Cocrystal Pharma's value examination focuses on studying past and present price action to predict the probability of Cocrystal Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cocrystal Pharma's price. Additionally, you may evaluate how the addition of Cocrystal Pharma to your portfolios can decrease your overall portfolio volatility.